RTP gene-tech startup lands deal worth $90M
Research Triangle Park-based StrideBio Inc., a gene-editing technology startup, announced a deal with Massachusetts-based Sarepta Therapeutics Inc. that could be worth $90 million…
Research Triangle Park-based StrideBio Inc., a gene-editing technology startup, announced a deal with Massachusetts-based Sarepta Therapeutics Inc. that could be worth $90 million…